Nguyen CM, Mendes MAS, Ma JD. Thiopurine methyltransferase (TPMT) genotyping to predict myelosuppression risk.
PLOS CURRENTS 2011;
3:RRN1236. [PMID:
21593964 PMCID:
PMC3094768 DOI:
10.1371/currents.rrn1236]
[Citation(s) in RCA: 40] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Accepted: 05/16/2011] [Indexed: 01/17/2023]
Abstract
Azathioprine (AZA), 6-mercaptopurine (6-MP), and thioguanine (TG) are thiopurine drugs. These agents are indicated for the treatment of various diseases including hematologic malignancies, inflammatory bowel disease (IBD), rheumatoid arthritis, and as immunosuppressants in solid organ transplants. Thiopurine drugs are metabolized, in part, by thiopurine methyltransferase (TPMT). TPMT displays genetic polymorphism resulting in null or decreased enzyme activity. At least 20 polymorphisms have been identified, of which, TPMT *2, *3A, *3B, *3C, and *4 are the most commonly studied. These polymorphisms have been associated with increased myelosuppression risk. TPMT genotyping may be useful to predict this risk.
Collapse